A5025950763- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Cancer Treatment and Pharmacology
- Acute Myeloid Leukemia Research
- Coronary Interventions and Diagnostics
- Eosinophilic Disorders and Syndromes
- CNS Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Nutrition and Health in Aging
- Cardiac Imaging and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Pharmacological Effects and Toxicity Studies
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Frailty in Older Adults
Jikei University School of Medicine
2016-2025
Liv Hospital
2024
Samsung Medical Center
2024
University Hospital Brno
2024
Charles University
2024
The Jikei University Hospital
2023-2024
Jikei University Kashiwa hospital
1999-2023
Anjo Kosei Hospital
2021
Suzuki (Japan)
2019
Tosei General Hospital
2019
Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most a relapse. Frontline lenalidomide therapy has increased the number of lenalidomide-refractory disease at time first
Background —Little is known regarding intravascular ultrasound (IVUS) criteria to determine the functional severity of coronary stenosis. Recently, fractional flow reserve (FFR) has emerged as a lesion-specific index stenosis that independent systemic hemodynamic variability. The present study was undertaken IVUS parameters for physiological Methods and Results —Fifty-one lesions in 42 patients were evaluated by means quantitative angiogram, IVUS, intracoronary pressure measurements. FFR...
LBA105 Background: Use of triplet/quadruplet therapies for 1L MM raises the need novel combinations at first relapse, which belantamab mafodotin (belamaf) combos may address. In DREAMM-7, BVd led to a significant improvement in progression-free survival (PFS) and strong trend improved overall (OS) vs daratumumab-Vd patients (pts) with ≥1 prior therapy. We report results from DREAMM-8 (NCT04484623), tested different belamaf combo (BPd) met its primary endpoint independent review...
Background: Daratumumab (DARA), lenalidomide (LEN), and dexamethasone (DEX, DRd) are one of standards care for patients with multiple myeloma (MM); however, the clinical impact relative dose intensity (RDI) remains unclear. In this retrospective study, aim was to analyze relationship between RDI outcomes in treated DRd. Methods: The numbers newly diagnosed, relapsed, and/or refractory MM were 40 71, respectively. Results: median patient age 74 years, RDIs DARA, LEN, DEX 84.0%, 39.4%, 14.6%,...
Novel agents inducing deeper responses have improved the prognosis of patients with multiple myeloma (MM). To assess minimal residual disease (MRD) and stratify achieving complete response (CR), advanced technologies such as EuroFlow next-generation flow cytometry (NGF) sequencing (NGS) are increasingly utilized. This prospective study evaluated in newly diagnosed MM undergoing autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy across Japanese medical...
Multiple myeloma (MM) is a hematologic malignancy characterized by monoclonal proliferation of plasma cells that leads to bone disease, including lytic lesions and osteoporosis [...]
Abstract Background Heart failure (HF) prevalence increases with age, and sarcopenia is a poor prognostic factor in patients HF. We aimed to evaluate the characteristics factors HF sarcopenia. Results retrospectively reviewed 256 consecutive admitted our hospital for between May 2018 2021, underwent dual-energy X-ray absorptiometry, were diagnosed The primary endpoint was all-cause mortality. prognoses evaluated compared left ventricular ejection fraction (LVEF) < 50% (reduced LVEF,...
New drugs for multiple myeloma (MM) have dramatically improved patients' overall survival (OS). Autologous stem cell transplantation (ASCT) remains the mainstay transplant-eligible MM patients. To investigate whether post-ASCT prognosis of patients has been by new drugs, we undertook a retrospective observational analysis using Transplant Registry Unified Management Program database in Japan. We analyzed 7323 (4135 men and 3188 women; median age, 59 years; range 16-77 years) who underwent...
The CONtrolling NUTritional status (CONUT) score represents the nutritional of patients with heart failure (HF). Although high CONUT scores on admission are associated increased risks cardiovascular (CV) events in HF, impact changes during hospitalization their long-term prognosis is unclear. This study aimed to investigate clinical outcomes HF after discharge.This observational included 1705 hospitalized who were discharged alive. categorized depending at and discharge into persistently...
The anti-CD38 antibody daratumumab (Dara) has been reported to improve the prognosis of multiple myeloma (MM) patients, but its use before autologous stem cell transplantation (ASCT) remains controversial. To clarify prognostic impact Dara ASCT on MM, we performed a retrospective observational analysis. We analyzed 2626 patients who underwent between 2017 and 2020. In comparison not administered (Dara- group) those (Dara+ group), 1-year progression-free survival (PFS) rates were 87.4% 77.3%...
A 74-year-old man with multiple myeloma was refractory to melphalan/prednisolone (MP), high-dose dexamethasone and VAD chemotherapy. He had the following poor prognostic factors: 1) extramedullary plasmacytomas, 2) massive myelomatous effusion, 3) increasing immature cells plasmablastic morphology, 4) predominance of MPC1-CD49e-CD45+ phenotype cells. Combination therapy thalidomide resulted in a rapid response partial remission despite his factors. The present case suggests that combination...
Autologous stem cell transplantation (ASCT) is the standard of care for myeloma patients who achieve partial response (PR) or better after induction therapy. However, its clinical significance in with suboptimal (SR) before ASCT, including stable disease (SD) and progressive (PD), has not been established. Additionally, functional high-risk, SR early PD within 12 months, was a poor prognostic factor up to now. This study aimed evaluate efficacy ASCT novel agent era. multicenter retrospective...
Bromodomain and extraterminal protein (BET) inhibitors suppress the expression of c-MYC. U266, a human myeloma cell line, expresses MYCL gene, but not c-MYC gene. Our aim was to analyse antimyeloma activity BET on U266 cells. Two inhibitors, I-BET151 JQ1, were tested. proliferation decreased 61.5 54.0% control after incubation with 500 nmol/l for 72 96 h 53.5 56.4% JQ1 by MTS tetrazolium, respectively. induced cycle arrest at G1 phase in cells, did induce apoptosis flow cytometry. According...
Remarkable advancements have been made in the treatment outcomes of multiple myeloma (MM) patients; however, for frail elderly patients, these are still insufficient. Elderly MM patients increasing, as their regimens. There is a heightened demand to assess order provide optimized treatments. While continuous more common when compared fixed-duration treatment, due risk interruption causing reduced survival rates, effectiveness and safety essential. Treatment goals vary each patient, but must...
The treatment strategy for gastric diffuse large cell lymphoma (DLBCL) has not been standardized in such as to the cycles of chemotherapy, dose radiation, or necessity surgery. Although results CHOP R-CHOP treatments have demonstrated good prognosis, controversial many cases.We retrospectively analyzed 40 DLBCL patients receiving chemotherapy with without radiation our institute. Those stages II-IV were treated six radiation; those stage I, we administered three radiation.The three-year...